MRNA Stock Recent News
MRNA LATEST HEADLINES
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.
Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The mRNA therapeutics market size has grown steadily in recent years. It will grow from $33.5 billion in 2023 to $34.76 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The mRNA therapeutics market size is expected to see steady growth in the next few years. It will grow to $40.69 billion in 2028 at a compound annual growth rate (CAGR) of 4%.
The latest trading day saw Moderna (MRNA) settling at $57.73, representing a -0.96% change from its previous close.
They won't remain southbound forever.
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moderna-lawsuit-submission-form?prid=107378&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moderna-lawsuit-submission-form?prid=107362&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA).
LOS ANGELES--(BUSINESS WIRE)--MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moderna-lawsuit-submission-form?prid=107285&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK CITY, NY / ACCESSWIRE / October 8, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").